High mutation count in new COVID-19 variants does not increase immune evasion, study finds

FHS
July 20, 2024
2:40 am

New research from UNC Charlotte’s Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two recent and prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to Omicron.

mRNA rabies vaccine induces durable immune response in macaques

Novel mRNA vaccine for rabies shows enhanced immune response with higher antibody levels and improved cross-neutralization, indicating potential for a broadly protective vaccine against related

June 27, 2023

ODM-212 by Orion for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 28, 2023

MindMed Shifts Focus to Nasdaq | Psychedelic Invest

Mind Medicine (MindMed) Inc. has decided to streamline its trading avenues by voluntarily withdrawing its common shares from the Cboe Canada listing, a decision set

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.